FDA clears first AI-powered medical device to detect common skin cancers
For the first time, the 300,000 U.S. primary care physicians can now be equipped to provide quantitative, point-of-care testing for all types of skin cancer.
This author has not written his bio yet.
But we are proud to say that Business Wire contributed 743 entries already.
For the first time, the 300,000 U.S. primary care physicians can now be equipped to provide quantitative, point-of-care testing for all types of skin cancer.
This approval marks the third indication for Keytruda in cervical cancer and the 39th indication for Keytruda in the United States.
Building on its predictive AI adherence targeting launched in September 2023, Swoop’s new audiences allow healthcare marketers to target patients and providers prior to a diagnosis, those most likely to adopt a newly launched therapy or progress to a new line of treatment and those with ideal formulary coverage.
The initiative aims to raise awareness of the role of virtual twins in accelerating medical research and delivering personalized care. On social media, Emma Twin will document how she, as a virtual twin, helps doctors and researchers better understand diseases and the effects of treatments, without risk to real patients.
AWS HealthScribe is a new HIPAA-eligible service that empowers healthcare software providers to build clinical applications that use speech recognition and generative AI to save clinicians time by generating clinical documentation.
Gilead receives the rights to exclusively license EVOQ’s NanoDisc Technology to develop and commercialize immunotherapy products for rheumatoid arthritis and lupus.
Equillium, Inc. and Metacrine, Inc. announced the mutual termination of their previously announced definitive merger agreement.
LEO Pharma A/S, a global leader in medical dermatology, has launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.
Olohan, formerly Google healthcare managing director, joins the celebrated global health commercialization partner as executive vice president, growth.
The transaction, valued at about $700 million, affirms Alcon’s commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to Alcon’s existing commercial expertise, maximizing the value of its diversified portfolio.